These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2508112

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Intravenous prostavasin--therapy in peripheral arterial occlusive disease in Fontaine's stages III and IV. Early and late results of a screening study.
    Heidrich H, Meuche C, Ranft J, Rummel S, Peters A.
    Prog Clin Biol Res; 1989; 301():411-6. PubMed ID: 2678131
    [No Abstract] [Full Text] [Related]

  • 24. [Intravenous infusions in the treatment of arterial occlusive diseases from the surgical point of view].
    Hugeneck J.
    Wien Med Wochenschr; 1976 Sep 17; 126(38):542-4. PubMed ID: 788353
    [No Abstract] [Full Text] [Related]

  • 25. Clinical effects of intravenous iloprost in patients with intermittent claudication.
    Müller-Bühl U, Diehm C, Krais T, Zimmermann R, Mörl H, Eckstein HH.
    Eur J Clin Pharmacol; 1987 Sep 17; 33(2):127-31. PubMed ID: 2446877
    [Abstract] [Full Text] [Related]

  • 26. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial.
    Belch JJ, McKay A, McArdle B, Leiberman P, Pollock JG, Lowe GD, Forbes CD, Prentice CR.
    Lancet; 1983 Feb 12; 1(8320):315-7. PubMed ID: 6130330
    [Abstract] [Full Text] [Related]

  • 27. [Use of prostaglandins in extracorporeal circulation and hemodialysis].
    Zaorska B.
    Pol Tyg Lek; 1981 Jun 08; 36(23):857-60. PubMed ID: 7024949
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Substances with vasoactive effects mediated by the prostaglandin system.
    Pallapies D, Peskar BA.
    Vasa Suppl; 1991 Jun 08; 33():75-6. PubMed ID: 1788770
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pharmacologic management of peripheral vascular disease.
    McNamara DB, Champion HC, Kadowitz PJ.
    Surg Clin North Am; 1998 Jun 08; 78(3):447-64. PubMed ID: 9673656
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.
    Müller B, Krais T, Stürzebecher S, Witt W, Schillinger E, Baldus B.
    Biomed Biochim Acta; 1988 Jun 08; 47(10-11):S40-4. PubMed ID: 2470358
    [Abstract] [Full Text] [Related]

  • 36. [Effect of the prostacyclin analog taprostene on ischemic ST-segment depression in the stress ECG of coronary patients].
    Hopf R, Schöfl E, Frings M, Söhngen W.
    Z Kardiol; 1994 Apr 08; 83(4):258-63. PubMed ID: 8023538
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure.
    Gimson AE, Langley PG, Hughes RD, Canalese J, Mellon PJ, Williams R, Woods HF, Weston MJ.
    Lancet; 1980 Jan 26; 1(8161):173-5. PubMed ID: 6101632
    [Abstract] [Full Text] [Related]

  • 39. Prevention of coagulation during hemodialysis by a combination of the stable prostacyclin analogue CG 4203 and low-dose heparin.
    Maurin N, Ballmann M.
    Clin Nephrol; 1988 Jul 26; 30(1):35-41. PubMed ID: 3061692
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.